The role of factor Xa inhibitors in venous thromboembolism treatment.
Article Details
- CitationCopy to clipboard
Cabral KP, Ansell JE
The role of factor Xa inhibitors in venous thromboembolism treatment.
Vasc Health Risk Manag. 2015 Jan 30;11:117-23. doi: 10.2147/VHRM.S39726. eCollection 2015.
- PubMed ID
- 25673997 [ View in PubMed]
- Abstract
Three factor Xa inhibitors have been studied in the treatment of venous thromboembolism, both for acute therapy and as extended therapy to prevent recurrent events. Rivaroxaban, apixaban, and edoxaban have all proven to be effective in Phase III clinical trials for this indication when compared to current standard of therapy with similar or less bleeding. Nevertheless, the agents all offer different pharmacological profiles, which have an impact on patient selection and potential advantages in clinical practice.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Betrixaban Coagulation factor X Protein Humans YesInhibitorDetails